Group 1 - The A-share innovative drug concept showed slight weakness after opening, while the Hong Kong pharmaceutical and biotechnology sector performed positively [1] - The Tianhong Innovative Drug ETF (517380) saw a rise of 0.30% after initially dropping nearly 0.9%, with a premium rate of 0.07% [1] - Major weighted stocks in the ETF, such as WuXi AppTec, Hengrui Medicine, and Innovent Biologics, performed well, while BeiGene saw declines [1] Group 2 - Chinese innovative drugs are at a critical turning point from quantitative to qualitative change, with broad prospects for growth [2] - Domestic pharmaceutical companies are shifting their business development (BD) focus from inward introduction to outward licensing [2] - The innovative drug sector has experienced rapid growth in product revenue and external licensing over the past three years, with significant BD transactions occurring this year [2]
昨日“吸金”超千万元，创新药ETF天弘（517380）盘中翻红，机构关注创新药行情全面扩散下的投资机会
2 1 Shi Ji Jing Ji Bao Dao·2025-06-11 02:33